RPT 1G
Alternative Names: RPT-1GLatest Information Update: 08 Jul 2026
At a glance
- Originator Remedy Plan Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
- Preclinical Solid tumours
Most Recent Events
- 22 Apr 2026 Pharmacodynamics data from a preclinical study in Solid tumour presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR 2026)
- 17 Apr 2026 Pharmacodynamics data from a preclinical study in Solid tumour presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR 2026) (ADNM)
- 17 Apr 2026 Pharmacodynamics and adverse events data from phase I trial in Haematological malignancies presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)